Please note, this OEL/ADE monograph also applies to cefuroxime axetil (CAS RN 64544-07-6) and cefuroxime sodium (CAS RN 56238-63-2). Cefuroxime is indicated for the treatment of susceptible bacterial infections including gonorrhea, bone and joint infections, skin and skin layer infections, lower respiratory tract infection, meningitis, sepsis and urinary tract infections. Cefuroxime sodium is a semisynthetic, broad-spectrum, cephalosporin antibiotic, which is highly stable to deactivation by certain gram-negative beta-lactamases. It exerts its bactericidal effect by inhibiting bacterial cell-wall synthesis. It has activity against a wide range of aerobic and anaerobic gram-positive and gram-negative organisms.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Cefuroxime, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.